Trial Profile
A Phase I, Randomized Double-blind, Placebo-controlled, Single Ascending Dose, Single-center Study to Assess the Safety, Tolerability and Pharmacokinetic of Yimitasvir in Healthy Adults Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2020
Price :
$35
*
At a glance
- Drugs Yimitasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Sunshine Lake Pharma
- 13 Mar 2018 New trial record